European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

A.K. Burnett, N.H. Russell, J. Kell, M. Dennis, D. Milligan, S. Paolini, J. Yin, D. Culligan, P. Johnston, J. Murphy, Mary Frances McMullin, A. Hunter, E. Das-Gupta, R. Clark, R.K. Hills

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

PURPOSE:
Treatment options for older patients with acute myeloid leukemia (AML) who are not considered suitable for intensive chemotherapy are limited. We assessed the second-generation purine nucleoside analog, clofarabine, in two similar phase II studies in this group of patients.
PATIENTS AND METHODS:
Two consecutive studies, UWCM-001 and BIOV-121, recruited untreated older patients with AML to receive up to four or six 5-day courses of clofarabine. Patients in UWCM-001 were either older than 70 years or 60 to 69 years of age with poor performance status (WHO > 2) or with cardiac comorbidity. Patients in BIOV-121 were >or= 65 years of age and deemed unsuitable for intensive chemotherapy.
RESULTS:
A total of 106 patients were treated in the two monotherapy studies. Median age was 71 years (range, 60 to 84 years), 30% had adverse-risk cytogenetics, and 36% had a WHO performance score >or= 2. Forty-eight percent had a complete response (32% complete remission, 16% complete remission with incomplete peripheral blood count recovery), and 18% died within 30 days. Interestingly, response and overall survival were not inferior in the adverse cytogenetic risk group. The safety profile of clofarabine in these elderly patients with AML who were unsuitable for intensive chemotherapy was manageable and typical of a cytotoxic agent in patients with acute leukemia. Patients had similar prognostic characteristics to matched patients treated with low-dose cytarabine in the United Kingdom AML14 trial, but had significantly superior response and overall survival.
CONCLUSION:
Clofarabine is active and generally well tolerated in this patient group. It is worthy of further evaluation in comparative trials and might be of particular use in patients with adverse cytogenetics.
Original languageEnglish
Pages (from-to)2389-2395
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number14
DOIs
Publication statusPublished - 10 May 2010

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)
  • Oncology

Fingerprint Dive into the research topics of 'European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.'. Together they form a unique fingerprint.

  • Cite this

    Burnett, A. K., Russell, N. H., Kell, J., Dennis, M., Milligan, D., Paolini, S., Yin, J., Culligan, D., Johnston, P., Murphy, J., McMullin, M. F., Hunter, A., Das-Gupta, E., Clark, R., & Hills, R. K. (2010). European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. Journal of Clinical Oncology, 28(14), 2389-2395. https://doi.org/10.1200/JCO.2009.26.4242